AICR awards $1.15 million for cancer prevention and survivorship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Seven researchers have received a total of $1.15 million from the American Institute for Cancer Research to study the relationship between diet, nutrition, physical activity, body weight and cancer prevention and survivorship.

The diverse research topics focus on cancers in women and men and identify a wide array of the most common risk factors and their impact on prevention, survivorship and recurrence.

The 2021 AICR research grantees are:

  • Christine Brainson, University of Kentucky Research Foundation: How dietary methionine influences lung cancer initiation and chemosensitivity,
  • Michael De Lisio, University of Ottawa: Aberrant myelopoiesis as a novel mechanism for the differential effects of obesity and exercise on colorectal cancer risk,
  • Brian Focht, Ohio State University: Addressing obesity to reduce cancer risk and health disparities in underserved populations,
  • Christopher Haiman, University of Southern California: Interactions of polygenic risk score with BMI, physical activity and dietary patterns on risk of breast, colorectal and prostate cancer in the Multiethnic Cohort,
  • Xin Lu, University of Notre Dame: Overcome resistance to cancer immunotherapy with ketogenic diet-induced epigenetic reprogramming,
  • Scherezade Mama, MD Anderson Cancer Center: Feasibility of an adapted multicomponent physical activity intervention to reduce psychosocial distress in rural adults following cancer diagnosis; and
  • Erik Nelson, University of Illinois at Urbana-Champaign: Determining the impact of different preparation techniques of foods high in cholesterol on breast cancer progression.

AICR has contributed more than $110 million to support over 750 studies conducted at universities, hospitals and research centers across North, South and Central America.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login